[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002213468A1 - Bile-acid conjugates for providing sustained systemic concentrations of drugs - Google Patents

Bile-acid conjugates for providing sustained systemic concentrations of drugs

Info

Publication number
AU2002213468A1
AU2002213468A1 AU2002213468A AU1346802A AU2002213468A1 AU 2002213468 A1 AU2002213468 A1 AU 2002213468A1 AU 2002213468 A AU2002213468 A AU 2002213468A AU 1346802 A AU1346802 A AU 1346802A AU 2002213468 A1 AU2002213468 A1 AU 2002213468A1
Authority
AU
Australia
Prior art keywords
bile
drugs
acid conjugates
providing sustained
systemic concentrations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213468A
Inventor
Kenneth C. Cundy
Mark A. Gallop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
XenoPort Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XenoPort Inc filed Critical XenoPort Inc
Priority claimed from PCT/US2001/042628 external-priority patent/WO2002028883A1/en
Publication of AU2002213468A1 publication Critical patent/AU2002213468A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2002213468A 2000-10-06 2001-10-09 Bile-acid conjugates for providing sustained systemic concentrations of drugs Abandoned AU2002213468A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23875800P 2000-10-06 2000-10-06
US60238758 2000-10-06
US24980400P 2000-11-17 2000-11-17
US60249804 2000-11-17
US29747201P 2001-06-11 2001-06-11
US60297472 2001-06-11
PCT/US2001/042628 WO2002028883A1 (en) 2000-10-06 2001-10-09 Bile-acid conjugates for providing sustained systemic concentrations of drugs

Publications (1)

Publication Number Publication Date
AU2002213468A1 true AU2002213468A1 (en) 2002-04-15

Family

ID=27399153

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002230398A Abandoned AU2002230398A1 (en) 2000-10-06 2001-10-05 Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002213468A Abandoned AU2002213468A1 (en) 2000-10-06 2001-10-09 Bile-acid conjugates for providing sustained systemic concentrations of drugs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002230398A Abandoned AU2002230398A1 (en) 2000-10-06 2001-10-05 Bile-acid conjugates for providing sustained systemic concentrations of drugs

Country Status (4)

Country Link
US (5) US6900192B2 (en)
EP (2) EP1361847A2 (en)
AU (2) AU2002230398A1 (en)
WO (1) WO2002032376A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
WO2002032376A2 (en) * 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1358200A4 (en) * 2000-10-06 2005-07-20 Xenoport Inc Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
EP2548447B1 (en) 2003-04-11 2017-09-27 Cargill, Incorporated Pellet systems for preparing beverages
JP2007505149A (en) 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド Treatment and / or prevention of urinary incontinence with prodrugs of GABA analogs
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2005037784A2 (en) 2003-10-14 2005-04-28 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CA2563252A1 (en) 2004-07-06 2005-03-31 Ksr International Co. Support bracket with an integrated switch for a pedal assembly
CN101068538A (en) 2004-11-04 2007-11-07 什诺波特有限公司 Gaba analog prodrug sustained release oral dosage forms
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2007065036A2 (en) * 2005-12-02 2007-06-07 Neuromolecular Pharmaceuticals, Inc. Therapeutic conjugates and methods of using same
JP2009530399A (en) * 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Compounds and methods for the treatment of diseases associated with ER stress
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
EA200970487A1 (en) * 2006-12-08 2009-12-30 Ксенопорт, Инк. APPLICATION OF GABA ANALOGUE PROCEDURES FOR TREATMENT OF DISEASES
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
JOP20180077A1 (en) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JP2010043063A (en) 2008-05-09 2010-02-25 Agency For Science Technology & Research Diagnosis and treatment of kawasaki disease
CA2729168A1 (en) * 2008-07-02 2010-02-04 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
MX2013001704A (en) 2010-08-12 2013-06-28 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods.
WO2012047495A2 (en) * 2010-09-27 2012-04-12 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US8741882B2 (en) * 2012-01-20 2014-06-03 Sen Capital, Llc. Anti-diabetic compounds
US9970929B2 (en) 2013-01-18 2018-05-15 Ark Diagnostics, Inc. Voriconazole immunoassays
WO2014126861A1 (en) 2013-02-13 2014-08-21 Ark Diagnostics, Inc. Posaconazole immunoassays
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
WO2016140799A1 (en) 2015-03-03 2016-09-09 Ark Diagnostics, Inc. Pregabalin immunoassays
WO2022211481A1 (en) 2021-04-01 2022-10-06 에스엔제이 파마 인크 Oral nanoparticles for bioactive compound, and method of preparing same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1294961B (en) * 1963-03-21 1969-08-21 Merck Ag E Process for the preparation of 22-azacholestane derivatives and their acid addition salts
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
US4560512A (en) 1982-09-30 1985-12-24 Merck & Co., Inc. Derivatives of steroid compounds linked to cyotoxic agents
DE3435386A1 (en) * 1984-09-27 1986-04-03 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart AIR-COOLED MULTI-CYLINDER INTERNAL COMBUSTION ENGINE
US4866044A (en) 1985-07-09 1989-09-12 Takeda Chemical Industries, Ltd. Solubilized composition of poorly-soluble pharmaceutical product
CH674369A5 (en) 1986-11-26 1990-05-31 Jago Res Ag
DE3930696A1 (en) 1989-09-14 1991-03-28 Hoechst Ag GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FI945426A0 (en) 1992-05-20 1994-11-18 Univ Northwestern GABA and L-glutamic acid analogs for anticonvulsant treatment
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5352682A (en) * 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
NO940115D0 (en) * 1994-01-13 1994-01-13 Nycomed Imaging As Contrast agents for X-ray and magnetic tomographic imaging
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
DE19508409C1 (en) * 1995-03-09 1996-05-09 Harting Elektronik Gmbh Multi-contact plug connector e.g. for circuit board
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5695738A (en) * 1995-06-15 1997-12-09 Glycomed Incorporated Steroidal C-glycosides
DE69616554T2 (en) * 1995-06-23 2002-07-11 Mitsubishi Chemical Corp., Tokio/Tokyo SIALIC DERIVATIVES
ATE218135T1 (en) 1996-02-07 2002-06-15 Warner Lambert Co CYCLIC AMINO ACID AS PHARMACEUTICAL AGENTS
JP2000506861A (en) 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー New substituted cyclic amino acids as pharmaceuticals
US6020370A (en) 1996-03-14 2000-02-01 Warner-Lambert Company Bridged cyclic amino acids as pharmaceutical agents
US6153650A (en) 1996-10-23 2000-11-28 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
DE29621794U1 (en) * 1996-12-17 1998-04-09 Robert Bosch Gmbh, 70469 Stuttgart Adjustment device, in particular for a sliding / lifting roof of a motor vehicle
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
JPH1160954A (en) 1997-08-21 1999-03-05 Toshiba Silicone Co Ltd Silicone binder composition
JPH1160594A (en) * 1997-08-25 1999-03-02 Sankyo Co Ltd Bile acid derivative
ES2260850T3 (en) 1997-10-27 2006-11-01 Warner-Lambert Company Llc CYCLINE AMINOACIDS AND ITS DERIVATIVES USED AS PHARMACEUTICAL AGENTS.
HUP0100069A3 (en) 1997-12-16 2002-04-29 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
TR200001795T2 (en) 1997-12-16 2000-11-21 Warner-Lambert Company 1-Substituted-1-Aminomethyl-cycloalkane derivatives (= Gabapentin analogues), their preparation and use in the treatment of neurological disorders.
KR20010033154A (en) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Novel Amines as Pharmaceutical Agents
BR9910697A (en) 1998-05-26 2001-01-30 Warner Lambert Co Structurally compressed amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
WO2000015611A1 (en) 1998-09-14 2000-03-23 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
WO2000023067A1 (en) 1998-10-16 2000-04-27 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
US6627771B1 (en) 1998-11-25 2003-09-30 Pfizer Inc Gamma amino butyric and acid analogs
IT1304501B1 (en) * 1998-12-23 2001-03-19 Bracco Spa USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE "BLOOD POOL AGENTS" FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
WO2001020331A1 (en) 1999-09-14 2001-03-22 Xenoport, Inc. Substrates and screening methods for transport proteins
WO2001076531A2 (en) 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1358200A4 (en) 2000-10-06 2005-07-20 Xenoport Inc Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Also Published As

Publication number Publication date
AU2002230398A1 (en) 2002-04-29
US20060166858A1 (en) 2006-07-27
US20020142998A1 (en) 2002-10-03
EP1347989A1 (en) 2003-10-01
EP1361847A2 (en) 2003-11-19
US20020111338A1 (en) 2002-08-15
US20050288228A1 (en) 2005-12-29
WO2002032376A2 (en) 2002-04-25
US20050148564A1 (en) 2005-07-07
US6984634B2 (en) 2006-01-10
WO2002032376A3 (en) 2003-09-04
US7601706B2 (en) 2009-10-13
US7049305B2 (en) 2006-05-23
US6900192B2 (en) 2005-05-31
US7598235B2 (en) 2009-10-06

Similar Documents

Publication Publication Date Title
AU2002230398A1 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002243204A1 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001235726A1 (en) Device for relative displacement of two bodies
AU2001267766A1 (en) Pyrazole derivatives
AU2001257577A1 (en) Water-soluble polymer conjugates of artelinic acid
AU2001242610A1 (en) Device for measuring a volume of drug
AU2882801A (en) Azepine derivatives
AU2002330273A1 (en) Liposome-encapsulated insulin formulations
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU2001264887A1 (en) Drug delivery device
AU2001236678A1 (en) Adamantyl derivatives as anti-cancer agents
AU2001240026A1 (en) Camptothecin conjugates
AU2002225878A1 (en) Receptor antagonist-lipid conjugates and delivery vehicles containing same
AU2001278694A1 (en) Avermectin derivatives
AU2002239257A1 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2001289635A1 (en) Polymeric conjugates of antitumor agents
AU2002332713A1 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2003287666A1 (en) Systemic delivery of antiviral agents
AU2001248772A1 (en) Sustained release drug compositions
AU2002221099A1 (en) Combination drugs
AU2001292122A1 (en) Heterocyclic derivatives useful as pharmaceutical agents
AU2001291690A1 (en) Drugs for sex dysfunctions
AU2001232244A1 (en) Drug comprising combination